Literature DB >> 29298051

CRISPRed Macrophages for Cell-Based Cancer Immunotherapy.

Moumita Ray1, Yi-Wei Lee1, Joseph Hardie1, Rubul Mout1, Gulen Yeşilbag Tonga1, Michelle E Farkas1, Vincent M Rotello1.   

Abstract

We present here an integrated nanotechnology/biology strategy for cancer immunotherapy that uses arginine nanoparticles (ArgNPs) to deliver CRISPR-Cas9 gene editing machinery into cells to generate SIRP-α knockout macrophages. The NP system efficiently codelivers single guide RNA (sgRNA) and Cas9 protein required for editing to knock out the "don't eat me signal" in macrophages that prevents phagocytosis of cancer cells. Turning off this signal increased the innate phagocytic capabilities of the macrophages by 4-fold. This improved attack and elimination of cancer cells makes this strategy promising for the creation of "weaponized" macrophages for cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29298051      PMCID: PMC6063311          DOI: 10.1021/acs.bioconjchem.7b00768

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  25 in total

1.  SHPS-1 regulates integrin-mediated cytoskeletal reorganization and cell motility.

Authors:  K Inagaki; T Yamao; T Noguchi; T Matozaki; K Fukunaga; T Takada; T Hosooka; S Akira; M Kasuga
Journal:  EMBO J       Date:  2000-12-15       Impact factor: 11.598

2.  Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.

Authors:  Mark P Chao; Ash A Alizadeh; Chad Tang; Max Jan; Rachel Weissman-Tsukamoto; Feifei Zhao; Christopher Y Park; Irving L Weissman; Ravindra Majeti
Journal:  Cancer Res       Date:  2010-12-21       Impact factor: 12.701

Review 3.  The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications.

Authors:  Mark P Chao; Irving L Weissman; Ravindra Majeti
Journal:  Curr Opin Immunol       Date:  2012-02-04       Impact factor: 7.486

4.  SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.

Authors:  Jun Chen; Ming-Chao Zhong; Huaijian Guo; Dominique Davidson; Sabrin Mishel; Yan Lu; Inmoo Rhee; Luis-Alberto Pérez-Quintero; Shaohua Zhang; Mario-Ernesto Cruz-Munoz; Ning Wu; Donald C Vinh; Meenal Sinha; Virginie Calderon; Clifford A Lowell; Jayne S Danska; André Veillette
Journal:  Nature       Date:  2017-04-19       Impact factor: 49.962

5.  Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy.

Authors:  Mark P Chao; Chad Tang; Russell K Pachynski; Robert Chin; Ravindra Majeti; Irving L Weissman
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

6.  Genome engineering using the CRISPR-Cas9 system.

Authors:  F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

7.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Authors:  Stephen B Willingham; Jens-Peter Volkmer; Andrew J Gentles; Debashis Sahoo; Piero Dalerba; Siddhartha S Mitra; Jian Wang; Humberto Contreras-Trujillo; Robin Martin; Justin D Cohen; Patricia Lovelace; Ferenc A Scheeren; Mark P Chao; Kipp Weiskopf; Chad Tang; Anne Kathrin Volkmer; Tejaswitha J Naik; Theresa A Storm; Adriane R Mosley; Badreddin Edris; Seraina M Schmid; Chris K Sun; Mei-Sze Chua; Oihana Murillo; Pradeep Rajendran; Adriel C Cha; Robert K Chin; Dongkyoon Kim; Maddalena Adorno; Tal Raveh; Diane Tseng; Siddhartha Jaiswal; Per Øyvind Enger; Gary K Steinberg; Gordon Li; Samuel K So; Ravindra Majeti; Griffith R Harsh; Matt van de Rijn; Nelson N H Teng; John B Sunwoo; Ash A Alizadeh; Michael F Clarke; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

8.  Quantitative tracking of protein trafficking to the nucleus using cytosolic protein delivery by nanoparticle-stabilized nanocapsules.

Authors:  Moumita Ray; Rui Tang; Ziwen Jiang; Vincent M Rotello
Journal:  Bioconjug Chem       Date:  2015-06-02       Impact factor: 4.774

9.  Direct delivery of functional proteins and enzymes to the cytosol using nanoparticle-stabilized nanocapsules.

Authors:  Chang Soo Kim; David J Solfiell; Subinoy Rana; Rui Tang; Rubul Mout; Elih M Velázquez-Delgado; Apiwat Chompoosor; Youngdo Jeong; Bo Yan; Zheng-Jiang Zhu; Chaekyu Kim; Jeanne A Hardy; Vincent M Rotello
Journal:  ACS Nano       Date:  2013-07-08       Impact factor: 15.881

10.  Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.

Authors:  Kipp Weiskopf; Aaron M Ring; Chia Chi M Ho; Jens-Peter Volkmer; Aron M Levin; Anne Kathrin Volkmer; Engin Ozkan; Nathaniel B Fernhoff; Matt van de Rijn; Irving L Weissman; K Christopher Garcia
Journal:  Science       Date:  2013-05-30       Impact factor: 47.728

View more
  27 in total

1.  Macrophage activation by a substituted pyrimido[5,4-b]indole increases anti-cancer activity.

Authors:  Joseph Hardie; Javier A Mas-Rosario; Siyoung Ha; Erik M Rizzo; Michelle E Farkas
Journal:  Pharmacol Res       Date:  2019-09-10       Impact factor: 7.658

2.  Macrophage circadian rhythms are differentially affected based on stimuli.

Authors:  Sujeewa S Lellupitiyage Don; Javier A Mas-Rosario; Hui-Hsien Lin; Evelyn M Nguyen; Stephanie R Taylor; Michelle E Farkas
Journal:  Integr Biol (Camb)       Date:  2022-06-08       Impact factor: 3.177

3.  In Vivo Editing of Macrophages through Systemic Delivery of CRISPR-Cas9-Ribonucleoprotein-Nanoparticle Nanoassemblies.

Authors:  Yi-Wei Lee; Rubul Mout; David C Luther; Yuanchang Liu; Laura Castellanos-García; Amy S Burnside; Moumita Ray; Gulen Yeşilbag Tonga; Joseph Hardie; Harini Nagaraj; Riddha Das; Erin L Phillips; Tristan Tay; Richard W Vachet; Vincent M Rotello
Journal:  Adv Ther (Weinh)       Date:  2019-08-15

Review 4.  Gene editing for immune cell therapies.

Authors:  Stefanie R Bailey; Marcela V Maus
Journal:  Nat Biotechnol       Date:  2019-06-03       Impact factor: 54.908

Review 5.  Therapeutic Genome Editing and In Vivo Delivery.

Authors:  Amanda Catalina Ramirez-Phillips; Dexi Liu
Journal:  AAPS J       Date:  2021-06-02       Impact factor: 4.009

Review 6.  Nanomedicine-based cancer immunotherapy: recent trends and future perspectives.

Authors:  Vinoth-Kumar Lakshmanan; Shlok Jindal; Gopinath Packirisamy; Shreesh Ojha; Sen Lian; Ajeet Kaushik; Abdulqadir Ismail M Abdullah Alzarooni; Yasser Abdelraouf Farahat Metwally; Sadras Panchatcharam Thyagarajan; Young Do Jung; Salem Chouaib
Journal:  Cancer Gene Ther       Date:  2021-02-08       Impact factor: 5.987

7.  12 Survival-related differentially expressed genes based on the TARGET-osteosarcoma database.

Authors:  Emel Rothzerg; Jiake Xu; David Wood; Sulev Kõks
Journal:  Exp Biol Med (Maywood)       Date:  2021-04-29

Review 8.  Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer.

Authors:  Samantha M Fix; Amir A Jazaeri; Patrick Hwu
Journal:  Cancer Discov       Date:  2021-02-09       Impact factor: 39.397

Review 9.  Macrophage reprogramming for therapy.

Authors:  Valentina M T Bart; Robert J Pickering; Philip R Taylor; Natacha Ipseiz
Journal:  Immunology       Date:  2021-01-25       Impact factor: 7.215

Review 10.  The Role of Ageing and Parenchymal Senescence on Macrophage Function and Fibrosis.

Authors:  Ross A Campbell; Marie-Helena Docherty; David A Ferenbach; Katie J Mylonas
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.